Submission Details
| 510(k) Number | K223161 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | October 07, 2022 |
| Decision Date | February 23, 2023 |
| Days to Decision | 139 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
K223161 is an FDA 510(k) clearance for the OXY-1 System, a Oxygenator, Cardiopulmonary Bypass (Class II — Special Controls, product code DTZ), submitted by Abiomed, Inc. (Danvers, US). The FDA issued a Cleared decision on February 23, 2023, 139 days after receiving the submission on October 7, 2022. This device falls under the Cardiovascular review panel. Regulated under 21 CFR 870.4350.
| 510(k) Number | K223161 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | October 07, 2022 |
| Decision Date | February 23, 2023 |
| Days to Decision | 139 days |
| Submission Type | Traditional |
| Review Panel | Cardiovascular (CV) |
| Summary | Summary PDF |
| Product Code | DTZ — Oxygenator, Cardiopulmonary Bypass |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 870.4350 |